Top Health Tech Companies in NYC, NY (864)

Investor Backing & Capital Strength: Capital momentum includes a $100M Series D in July 2024 at a higher valuation, signaling strong support for continued expansion. The raise is characterized as a notable step-up in a challenging health-tech funding climate.

Market Expansion: Geographic and payer reach are widening with nationwide availability and announced rollouts into Medicare Advantage by late 2024 and Medicaid in 2025. Broader plan connectivity and integrated primary care referral pathways indicate growth beyond the original commercial focus.

Strong Revenue Growth: Revenue is described as more than doubling over the prior 12 months alongside rising appointment volume and a rapidly expanding provider network. Milestones such as 1,000,000+ patients connected and millions of care hours delivered reinforce throughput growth.

Profitability: Profitability is highlighted as first achieved in 2023 and sustained thereafter, with the company also describing itself as cash‑flow positive. These signals point to durable unit economics and financial health.

Strong Revenue Growth: Revenue is described as growing quickly over multiple years with momentum expected to continue, while efficiency benchmarks such as the Rule of 40 have been surpassed. Together, these indicators suggest efficient, scalable growth.

Strategic Partnerships: New integrations and channels—such as embedded real‑time booking on Yelp, Healthgrades, and Google’s Gemini, along with payer partnerships—are expanding distribution and reinforcing growth. These collaborations broaden patient access points and help providers secure bookings.

Investor Backing & Capital Strength: Recent financings include a strategic Series C with Dassault Syst�fsmes/Medidata (March 2025) and a Series D in April 2026 led by Boehringer Ingelheim tied to CT-155 commercialization. The restructuring with Boehringer also involved additional funding as commercialization responsibilities shifted to Click.

Product Line Growth: FDA authorizations for Rejoyn (MDD, 2024) and CT-132 (migraine prevention, 2025), plus the acquisition of AspyreRx (type 2 diabetes), expand the marketed and near-market portfolio. The launch of "Click SE" and CT-155s Breakthrough designation and positive pivotal data further broaden the offering toward potential submission.

Strategic Partnerships: Collaborations with Boehringer Ingelheim, Otsuka, and Dassault Syst�fsmes/Medidata, along with a 2026 venture with Ultrahuman, indicate strong external validation and routes to commercialization. Partner activity includes Boehringer transferring commercialization duties for CT-155 to Click.

Investor Backing & Capital Strength: Significant financing—a $55M Series B led by Transformation Capital with continued support from existing investors—brings total venture backing above $70M and provides clear runway to scale. Leadership links this capital to expanding engineering, product, and growth teams to meet rising demand.

Innovation-Driven Growth: The platform emphasizes agentic/generative AI (e.g., Autodor AI Agents) to move from reactive post‑payment review to proactive pre‑payment detection. Reported results include faster claim turnaround times and measurable medical cost savings for payer clients.

Market Expansion: Engagements span regional and national health plans (including partnerships such as Johns Hopkins Health Plans), with teams scaling to address rising demand. Activity across prior authorization, payment integrity, and appeals points to a widening footprint in health‑plan operations.

Investor Backing & Capital Strength: Back-to-back Series D ($118M, Feb 2026) and Series E ($100M, May 2026) at step-up valuations to roughly $1.35B and $2.74B point to ample runway and strong investor confidence. Participation from firms such as Index Ventures, Kleiner Perkins, Sequoia, Thrive, Founders Fund, Redpoint, and Kaiser Permanente Ventures underscores capital strength.

Strong Revenue Growth: Company disclosures cite approximately $200M in gross annual recurring revenue with revenue more than doubling for five consecutive years, including over 130% year-over-year growth noted in early 2026. Nearly 800 customers and millions of covered members are also cited as evidence of expanding commercial scale.

Strategic Partnerships: New collaborations in 2026 with Priority Health and Atlantic Health expand distribution into health plan and regional employer channels. Priority Health separately confirmed the partnership and product launch.

Profitability: Adjusted EBITDA remained robust in 2025 (about $270M, ~34% margin) and 2026 guidance was lifted to $240–$250M, indicating healthy margins despite softer top-line trends. Strong quarterly EBITDA and cash generation in 1H 2026 underscore financial durability through the transition.

Diversified Revenue Streams: Pharma Direct and subscriptions are scaling quickly (Pharma Direct +41% in 2025 and +76–82% YoY in 1H 2026; subscriptions +16% in Q1 and +39% in Q2 2026), broadening the mix beyond the legacy coupon business. Management continues to position these segments as key growth drivers that can offset core declines over time.

Product Line Growth: New offerings such as condition‑specific programs (notably weight‑loss/GLP‑1), the GoodRx Companion membership, and initiatives like Employer Direct expand the product footprint. Deeper manufacturer relationships and program integrations (including presence on the federal TrumpRx.gov platform) further extend the solution set.

Strong Revenue Growth: Revenue expanded rapidly, with FY2025 up 83% to about $1.27B and Q1/Q2 2026 up 36% and 22% year over year, respectively. Management also raised 2026 revenue guidance to approximately $1.595–$1.605B.

Diversified Revenue Streams: Both Diagnostics and Data & Applications are expanding, with Diagnostics up 34.7% in Q1 and 20% in Q2 2026 and Insights/data licensing up 36% in Q2 alongside about $200M in new licenses. Rising oncology test volumes (28–31% YoY) and accelerating MRD tests (~4,700 in Q4 2025 to ~9,000 in Q2 2026) reinforce multiple growth engines.

Profitability: The company achieved its first GAAP-profitable quarter in Q2 2026 (net income about $5.6M; Adjusted EBITDA ~$8.0M). Guidance points to further improvement in 2026, indicating progress toward sustained profitability.

Market Expansion: International partnerships across the UK, Germany, and Japan—culminating in a first Scottish agreement in 2026—are described as tripling the network in 2025 and adding nearly 70% ex‑U.S. growth in 2026. These moves indicate a materially broader geographic footprint for evidence generation.

Strategic Partnerships: Collaborations with organizations such as NHS Greater Glasgow and Clyde, Quest Diagnostics, Abbott, TailorMed, and Unicancer reflect deepening integration at the point of care and with research stakeholders. These relationships suggest expanding routes to market and data acquisition.

Product Line Growth: New offerings like Flatiron Telescope, AI‑powered oncology datasets, and an AI data‑quality/validation framework signal active investment in products and capabilities. Conference acceptances at ISPOR/ASCO/WCLC in 2026 further underscore ongoing commercialization and scientific engagement.

Investor Backing & Capital Strength: Multiple trackers point to a mid‑2024 round with firms like Forerunner and RRE involved, indicating investor confidence and available runway. Third‑party activity scores have risen recently, reinforcing a picture of increasing momentum.

Strong Hiring & Retention: Active postings across engineering and advocate roles, a live careers page, and listings in the 11–50 range indicate ongoing team expansion. Some sources note recent quarter‑over‑quarter headcount gains consistent with early‑stage scaling.

Market Expansion: New distribution via benefits channels—such as StretchDollar and a program for Mesquite ISD employees via First Financial Group of America—extends reach beyond direct‑to‑consumer. A live iOS app alongside fresh GTM/pricing updates suggests active go‑to‑market execution.

Investor Backing & Capital Strength: A new $10 million raise in July 2026, described as part of a $30M+ round, alongside recent SEC filings indicates continued capital formation to fund expansion and hiring. Prior institutional backing provides runway to execute growth plans.

Strong Hiring & Retention: The company’s Greenhouse jobs board lists current openings in peer support and outreach roles, signaling active headcount additions rather than a freeze. Continued expansion of these roles would demonstrate that growth plans are being operationalized.

Market Expansion: The company’s site shows operations across Florida, Ohio, Michigan, Virginia, and Washington, evidencing a multi‑state footprint with room to deepen as funding allows. Active recruiting across these states supports ongoing build‑out.

Investor Backing & Capital Strength: A third funding round reported as a Series C in June 2024, bringing total raised to $200M+, is presented as a scaling‑stage milestone and foundation for continued investment. This capital base aligns with ongoing product rollouts and market expansion efforts.

Strategic Partnerships: Cleveland Clinic expanded its enterprise deployment in 2025, and the Clinic’s own materials later highlighted systemwide use of AKASA’s generative‑AI tools for coding and documentation across U.S. locations. These multi‑site, referenceable wins indicate traction with major health systems.

Product Line Growth: Successive mid‑cycle launches in 2024–2025 (e.g., Authorization Advisor, AKASA Medical Coding, CDI Optimizer) highlight continued R&D and commercialization. This expansion signals a broader roadmap beyond an initial single‑product focus.

Market Expansion: Headcount and footprint are described as rising to more than 15,000 employees across 40-plus offices, alongside concrete new sites in Hyderabad and a completed Chicago buildout—signals of geographic and capacity expansion. These moves indicate confidence in demand across key delivery hubs.

Innovation-Driven Growth: A dedicated Platforms & Products unit, the ZAIDYN portfolio, and AI-agent initiatives point to sustained investment in productized, AI-enabled offerings. Capability-deepening acquisitions (Digital Additive in 2024 and Torrent Consulting in 2025) further strengthen CRM and multi‑cloud life‑sciences solutions.

Strategic Partnerships: An expanded Salesforce collaboration around Agentforce and recognition as Databricks 2025 Life Sciences Partner of the Year suggest momentum in data/AI ecosystems. These alliances position the firm to capture spend where CRM, data, and AI converge in healthcare and life sciences.

Investor Backing & Capital Strength: Large late-stage financing and valuation momentum signal strong access to capital, including a $250M Series E and corroborated unicorn-scale valuations. Capital depth is further reinforced by indications of continued fundraising interest.

Strategic Partnerships: Embedded distribution with Zillow Rentals’ AI Assist, powered by EliseAI, is reported to drive higher renter engagement and application behavior. Such channel access expands reach and evidences measurable impact in real-world funnels.

Strong Revenue Growth: Company disclosures indicate surpassing $200M in ARR with continued acceleration from earlier milestones. Adoption signals across large operators align with sustained top-line expansion.

Investor Backing & Capital Strength: Capital raised includes a $100 million Series B in 2025 (with an additional Series B–II tracked) led by Insight Partners, positioning the company with substantial late-stage funding. These rounds are described as fueling national expansion of go-to-market and product.

Market Expansion: Deployments are expanding across senior living operators, with named rollouts at Friendship Village, Heritage Communities, Solera Senior Living, Aegis Living, Watercrest, and a portfolio-wide implementation at Arrow Senior Living. Case examples cite improved response times, reduced fall injuries, and longer lengths of stay, indicating growing footprint and product–market fit.

Innovation-Driven Growth: Product evolution includes launching a unified AI ecosystem, Inspiren HQ with the Inspiren Intelligence analytics layer, and eCall enhancements such as Two-Way Voice and Alert Claiming. Industry recognition like Fast Company’s Most Innovative Companies and a McKnight’s Technology Award tie to what the company calls a period of “record growth.”

Investor Backing & Capital Strength: Formation Bio closed a $372M Series D on June 26, 2024 led by a16z with significant participation from Sanofi, bringing total funding to over $600M and at a material step-up in valuation. The capital is directed toward expanding its drug pipeline and AI platform.

Strategic Partnerships: A first‑in‑class AI collaboration with Sanofi and OpenAI (announced May 2024) has already produced Muse, an AI tool for patient recruitment. Additional partnering activity includes Sanofi’s 2025 deal for gusacitinib via a Formation subsidiary, signaling expanding commercial and technology ties.

Product Line Growth: Multiple in‑licensing moves in 2025–2026 (e.g., a CNS‑penetrant TYK2 inhibitor, a miR‑124 activator, and an anti‑CD226 program) broaden the portfolio. The first participant was dosed in a Phase 1 trial (BLKR201) on June 9, 2026, marking concrete clinical progression.

Investor Backing & Capital Strength: A $30M Series A led by Optum Ventures in March 2022, with participation from Cigna Ventures, provides runway and signals strong institutional confidence. This capital supports continued platform development and go‑to‑market efforts described since 2023.

Future-Ready Strategy: The October 10, 2023 divestiture of TPA operations to Vitori Health refocused the company on payer data exchange and an integration/iPaaS platform. This deliberate move is presented as enabling scale in the core software business.

Innovation-Driven Growth: Product evolution spans Flume OS (2021) and Flume Relay (March 2023), with active documentation and positioning around a healthcare payer integration layer. These launches and ongoing materials indicate a maturing, software‑centric platform into 2025–2026.

Strong Revenue Growth: Total revenue increased to $255.9M in 2025 with software up and drug‑discovery more than doubling, while operating expenses declined year over year. Early 2026 also showed momentum, with first‑half revenue modestly higher and Q2 posting year‑over‑year growth.

Strategic Partnerships: New and expanded agreements—such as Bristol Myers Squibb deploying Bunsen and a July 2026 discovery collaboration with Simcere—broaden platform use and collaboration optionality. The Lilly/Ajax transaction also validated the model and supported a higher 2026 drug‑discovery outlook.

Product Line Growth: The introduction of Bunsen, an agentic AI co‑scientist, expands the software portfolio and is being deployed at scale within BMS. This product push complements growth in ACV and broader platform adoption.

Market Expansion: Customer base is described as rising from “more than 23,000” hospitals in 2024 to “more than 25,000” into 2025–2026 across all 50 states. Ecosystem updates and enterprise portals for hospital groups point to continued adoption and deeper penetration.

Strong Hiring & Retention: Headcount is indicated in the mid-300s by March 2026 (roughly 342–352 employees), with ongoing job postings through mid‑2026. This staffing trajectory reflects organizational scaling to support a larger footprint.

Strategic Partnerships: Recent and updated integrations with IDEXX Neo (June 18, 2026), Digitail (Aug 12, 2025), and DaySmart Vet (2025–2026) signal active partner growth. Such integrations embed the platform in daily veterinary workflows.

Investor Backing & Capital Strength: Advent International agreed on August 25, 2025 to acquire PatientPoint, with reporting at more than $1.4B, providing external validation and resources to accelerate expansion. This backing is positioned to support network growth and product innovation.

Product Line Growth: In March 2026 PatientPoint launched programmatic buying (Health Audiences) and a Consumer Health Network aimed at CPG/OTC brands, expanding how advertisers can buy and who the company serves. These additions broaden monetization beyond traditional life‑sciences sponsors.

Strong Market Position & Advantage: PatientPoint reports a nationwide footprint in 30,000+ physician offices and 125,000 providers, and in April 2026 received expanded Media Rating Council accreditation across its full digital screen network. This scale and third‑party validation bolster credibility for national buys.

Investor Backing & Capital Strength: Fresh equity and debt in 2026—a $65M Series C in March and a $35M facility in July—provide resources to scale product and go-to-market, with management noting total 2026 funding surpassed $100M. These financings are corroborated by company disclosures and press coverage.

Market Expansion: Company communications describe expansion into hundreds of communities across multiple states, with named operators such as Navion and Novellus moving from pilots to broader rollouts. These signals point to cohort expansion rather than isolated deployments.

Strategic Partnerships: Live integrations with ALIS, ECP, and Yardi—plus PointClickCare and August Health slated in 2026—are positioned to extend reach across a large share of senior‑living workflows. The company frames these connections as enablers of nationwide deployment and day‑to‑day interoperability.